Flavio G. Vincenti

MD

Kidney and pancreas transplant specialist

Dr. Flavio Vincenti is a specialist in kidney and pancreas transplantation. He came to UCSF Medical Center in 1975 for a fellowship in transplant nephrology and was appointed a member of the kidney transplant team.

In 1978, Vincenti co-authored an article in the New England Journal of Medicine on the role of blood transfusions in improving kidney transplants. He also wrote a series of articles on the complications of transplants and has been a leading investigator and writer on the use of anti–interleukin 2 receptor monoclonal antibodies, used to reduce the chance of organ rejection. In addition, he is a proponent of minimizing immunosuppressive drugs after transplants.

Vincenti is a member of many professional organizations, including the Transplantation Society, American Society of Nephrology, American Society of Transplantation and International Society of Nephrology. He is a co-leader of the Immune Tolerance Network's kidney section. In addition, he is on the editorial boards of Graft and the American Journal of Kidney Diseases.

  • Education

    American University Medical Center of Beirut, 1971

  • Residencies

    American University Medical Center of Beirut, Internal Medicine

  • Fellowships

    Emory University Hospital, Nephrology, 1975

  • Board Certifications

    Internal Medicine, American Board of Internal Medicine

    Nephrology, American Board of Internal Medicine

  • Academic Title

    Professor

  • Languages

    Arabic

    French

    Italian

Conditions I specialize in

Where I see patients (2)

    Selected research

    Decorative Caduceus

    Treg Therapy in Subclinical Inflammation in Kidney Transplantation

    The safety of polyTregs will be described in comparison with CNI-based maintenance IS therapy.

    Recruiting

    Decorative Caduceus

    Daratumumab and Belatacept for Desensitization

    Proportion of subjects who have not met a subject stopping rule, and remain free of all of the following through 26 weeks after starting treatment or until receiving a transplant, whichever occurs earlier: Grade 3 or higher infus...

    Recruiting

    Contact me

    Providers on my team

    Share